Rapidly progressive dementia (RPD) can be challenging to diagnose. The differential diagnosis is broad and includes many potentially reversible conditions. As many RPD are treatable if addressed early, quick diagnosis is important. Through presentation of common and challenging cases, faculty will review the differential diagnosis of RPD, the approach, and management strategies. This session will focus on prion and antibody-mediated disorders. At the conclusion of this program, attendees are invited to "continue the conversation" by engaging in small group conversation with the director and faculty. This program complements: Assessment of Rapidly Progressive Dementias I: Prion and Non-prion Neurodegenerative Diseases, but covers independent topics.

Completion Message:

Participants should be familiar with the differential diagnosis of prion and antibody-mediated causes of RPD and the clinical presentation and evaluation of the more common conditions.

CME Credits:

2

Core Competencies:

Patient Care, Medical Knowledge

Program Speakers - Tentative

Start/End Time

Title

Faculty

3:30 PM - 3:35 PM

Introduction

Michael D. Geschwind MD, PhD, FAAN

3:35 PM - 4:25 PM

Infections as Rapidly Progressive Dementia

Allen J. Aksamit MD, FAAN

4:25 PM - 5:15 PM

Autoimmune Causes of Rapidly Progressive Dementia

Jeffrey Marc Gelfand MD, MAS, FAAN

5:15 PM - 5:30 PM

Questions and Answers

Faculty

5:30 PM - 6:00 PM

Continuing the Conversation

Faculty

Disclosures

Speaker

Disclosure

Allen J. Aksamit, Jr., MD, FAAN

Dr. Aksamit has nothing to disclose.

Jeffrey Marc Gelfand, MD, MAS, FAAN

Dr. Gelfand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Alexion. His spouse has received personal compensation for consulting for Theranica, Impel Neuropharma, Eli Lilly, Impax and Zosano and to UCSF from eNeura. Dr. Gelfand personal fees as an expert for medical legal consulting from Alkem Laboratories Ltd., Accord Healthcare Inc, Apotex Corp., Apotex Inc., Teva Pharmaceuticals USA, Inc., Roxane Laboratories, Inc., Mylan Pharmaecuticals Inc., Merck, and from the United States Department of Health and Human Services and United States Department of Justice (Vaccine Injury Compensation Program). His spouse has also received personal fees for medical legal consulting. Dr. Gelfand has received personal compensation in an editorial capacity for content review for Dynamed Plus. He serves on the editorial advisory board for Neurology Neuroimmunology and Neuroinflammation. Dr. Gelfand's spouse received honoraria from JAMA Neurology as an Associate Editor and honoraria for writing from UptoDate . Dr. Gelfand has received research support from Genentech (to UCSF) for a clinical trial; he received service contract support from MedDay (to UCSF) for a clinical trial. His spouse received research support from Amgen (to UCSF).